Neoplasm Malignant
Conditions
Brief summary
Primary Objective: \- To assess the safety, tolerability and plasma pharmacokinetics (PK) of SAR245408 given once daily as a tablet formulation of polymorph E in subjects with solid tumors or lymphoma.
Detailed description
Screening: 1 to 28 days Study treatment period: two 28-day cycles (56 days) End-of-treatment visit: no later than 7 days after the last study drug administration Subjects not eligible for treatment continuation after Cycle 2 will be followed up for safety; a follow-up visit will be performed within 30 ± 3 days after the last study drug administration Subjects eligible for treatment continuation after Cycle 2 will be offered the opportunity to enroll in the treatment-extension study TED12414. Total duration of study participation for each patient: 58 to 118 days.
Interventions
DRUGSAR245408
Pharmaceutical form: tablet Route of administration: oral
Sponsors
Sanofi
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
: * Solid tumor that is metastatic or unresectable, or relapsed or refractory lymphoma (including chronic lymphocytic leukemia/small lymphocytic lymphoma), for which standard therapies are no longer effective or there are no therapies known to prolong survival or patient cannot tolerate or has contra-indication for a standard therapy and there is no alternative therapies. * Male or female patient \> or = 18 years old. * Weight \> or = 40 kg. * Eastern Cooperative Oncology Group performance status \< or = 1. * Adequate white blood cells, platelets, and haemoglobin. * Adequate liver and kidney functions. * Fasting plasma glucose \< 8.9 mmol/L. * Sexually active patients using adequate contraception. * Women of child-bearing potential with negative pregnancy test.
Exclusion criteria
* Lymphoma involving the gastrointestinal tract. * Prior treatment with cytotoxic chemotherapy (including investigational agents) or biologic agents (antibodies, immune modulators, and cytokines) within 4 weeks, or nitrosoureas or mitomycin C within 6 weeks, before the first dose of study drug. * Prior treatment with a small-molecule kinase inhibitor (including investigational agents) within 2 weeks, or 5 half lives of the drug or active metabolites, whichever is longer, before the first dose of study drug. * Any other investigational therapy within 4 weeks before the first dose of study drug. * Intolerance to prior treatment with a PI3K inhibitor. * Prior anticancer hormonal therapy within 2 weeks before the first dose of study drug. * Prior radiation therapy within 2 weeks before the first dose of study drug. * Uncontrolled brain metastases or primary brain tumor. * Hereditary or acquired immunodeficiency syndrome or human immunodeficiency virus (HIV) infection. * Positive serologies for Hepatitis B surface antigen (HBsAg) or anti-Hepatitis C virus (anti-HCV) antibodies. * Patient is pregnant or breastfeeding. * History of gastrointestinal surgery, or presence of gastrointestinal abnormality or disease, that may affect the pharmacokinetics of study drug. The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Dose Limiting Toxicities | Up to Day 28 |
Secondary
| Measure | Time frame |
|---|---|
| Number of patients with treatment-emergent adverse events | From first dose of SAR245408 up to 30 days after the last dose |
| Maximum SAR245408 plasma concentration | Days 1, 2, 8, 15, 29 and 30 |
| Area under the SAR245408 plasma concentration versus time curve | Days 1, 2, 8, 15, 29 and 30 |
Countries
Belgium
Outcome results
None listed